Literature DB >> 28029328

When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma.

Kimberly Perez1, Thomas E Clancy1, Joseph D Mancias1, Michael H Rosenthal1, Brian M Wolpin1.   

Abstract

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 64-year-old woman with a history of hypertension and type 2 diabetes had been in her usual state of health until she developed symptoms of diarrhea, abdominal bloating, and discomfort in the midepigastrium. Evaluation with a contrast-enhanced abdominopelvic computed tomography (CT) scan demonstrated a mass in the pancreatic body that was approximately 3.1 cm × 2 cm × 2.1 cm in size with abutment of the portal vein-superior mesenteric vein confluence for less than 180°. The confluence was narrowed but without thrombosis. No tumor-vessel interface was noted at the superior mesenteric artery, celiac artery, or common hepatic artery. Several peripancreatic lymph nodes were observed that measured up to 11 mm × 5 mm. No evidence for distant spread of disease was identified. An upper endoscopy with endoscopic ultrasound was performed and fine-needle aspirates of the pancreas mass were positive for malignant cells that were consistent with adenocarcinoma. Chest CT scan without intravenous contrast demonstrated no evidence of metastatic disease. The patient came to the clinic to discuss management of her newly diagnosed malignancy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28029328      PMCID: PMC5455317          DOI: 10.1200/JCO.2016.70.2134

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

1.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

2.  Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.

Authors:  William F Regine; Kathryn A Winter; Ross Abrams; Howard Safran; John P Hoffman; Andre Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett
Journal:  Ann Surg Oncol       Date:  2011-03-10       Impact factor: 5.344

3.  Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

Authors:  Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

4.  Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alok A Khorana; Pamela B Mangu; Jordan Berlin; Anitra Engebretson; Theodore S Hong; Anirban Maitra; Supriya G Mohile; Matthew Mumber; Richard Schulick; Marc Shapiro; Susan Urba; Herbert J Zeh; Matthew H G Katz
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

5.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

6.  Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Authors:  Cristina R Ferrone; Giovanni Marchegiani; Theodore S Hong; David P Ryan; Vikram Deshpande; Erin I McDonnell; Francesco Sabbatino; Daniela Dias Santos; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Jason E Faris; Lipika Goyal; Eunice L Kwak; Janet E Murphy; David T Ting; Jennifer Y Wo; Andrew X Zhu; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

Review 7.  Surgery for Pancreatic Cancer.

Authors:  Thomas E Clancy
Journal:  Hematol Oncol Clin North Am       Date:  2015-05-30       Impact factor: 3.722

8.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

Authors:  Douglas B Evans; Gauri R Varadhachary; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Huamin Wang; Karen R Cleary; Gregg A Staerkel; Chusilp Charnsangavej; Elizabeth A Lano; Linus Ho; Renato Lenzi; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

9.  Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.

Authors:  Henriette Golcher; Thomas B Brunner; Helmut Witzigmann; Lukas Marti; Wolf-Otto Bechstein; Christiane Bruns; Henry Jungnickel; Stefan Schreiber; Gerhard G Grabenbauer; Thomas Meyer; Susanne Merkel; Rainer Fietkau; Werner Hohenberger
Journal:  Strahlenther Onkol       Date:  2014-09-25       Impact factor: 3.621

10.  Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.

Authors:  Charles C Hsu; Joseph M Herman; Michele M Corsini; Jordan M Winter; Matthew D Callister; Michael G Haddock; John L Cameron; Timothy M Pawlik; Richard D Schulick; Christopher L Wolfgang; Daniel A Laheru; Michael B Farnell; Michael J Swartz; Leonard L Gunderson; Robert C Miller
Journal:  Ann Surg Oncol       Date:  2010-01-20       Impact factor: 5.344

View more
  5 in total

1.  Diffusion MRI biomarkers predict the outcome of irreversible electroporation in a pancreatic tumor mouse model.

Authors:  Matteo Figini; Xifu Wang; Tianchu Lyu; Zhanliang Su; Bin Wang; Chong Sun; Junjie Shangguan; Liang Pan; Kang Zhou; Quanhong Ma; Vahid Yaghmai; Daniele Procissi; Andrew C Larson; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

2.  Effect of route of administration on the efficacy of dendritic cell vaccine in PDAC mice.

Authors:  Jia Yang; Aydin Eresen; Junjie Shangguan; Quanhong Ma; Zhuoli Zhang; Vahid Yaghmai
Journal:  Am J Cancer Res       Date:  2020-11-01       Impact factor: 6.166

3.  Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Zhi Rong Qian; Douglas A Rubinson; Jonathan A Nowak; Vicente Morales-Oyarvide; Richard F Dunne; Margaret M Kozak; Marisa W Welch; Lauren K Brais; Annacarolina Da Silva; Tingting Li; Wanwan Li; Atsuhiro Masuda; Juhong Yang; Yan Shi; Mancang Gu; Yohei Masugi; Justin Bui; Caitlin L Zellers; Chen Yuan; Ana Babic; Natalia Khalaf; Andrew Aguirre; Kimmie Ng; Rebecca A Miksad; Andrea J Bullock; Daniel T Chang; Jennifer F Tseng; Thomas E Clancy; David C Linehan; Jennifer J Findeis-Hosey; Leona A Doyle; Aaron R Thorner; Matthew Ducar; Bruce Wollison; Angelica Laing; William C Hahn; Matthew Meyerson; Charles S Fuchs; Shuji Ogino; Jason L Hornick; Aram F Hezel; Albert C Koong; Brian M Wolpin
Journal:  JAMA Oncol       Date:  2018-03-08       Impact factor: 31.777

4.  Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival.

Authors:  Vicente Morales-Oyarvide; Douglas A Rubinson; Richard F Dunne; Margaret M Kozak; Justin L Bui; Chen Yuan; Zhi Rong Qian; Ana Babic; Annacarolina Da Silva; Jonathan A Nowak; Natalia Khalaf; Lauren K Brais; Marisa W Welch; Caitlin L Zellers; Kimmie Ng; Daniel T Chang; Rebecca A Miksad; Andrea J Bullock; Jennifer F Tseng; Richard S Swanson; Thomas E Clancy; David C Linehan; Jennifer J Findeis-Hosey; Leona A Doyle; Jason L Hornick; Shuji Ogino; Charles S Fuchs; Aram F Hezel; Albert C Koong; Brian M Wolpin
Journal:  Br J Cancer       Date:  2017-10-05       Impact factor: 7.640

5.  HSP27 promotes epithelial-mesenchymal transition through activation of the β-catenin/MMP3 pathway in pancreatic ductal adenocarcinoma cells.

Authors:  Zehong Fang; Wenjin Liang; Laibang Luo
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.